Sign in

    Tejas Vyas

    Research Analyst at UBS

    Tejas Vyas is an analyst at UBS specializing in equity research, with a focus on evaluating companies in key market sectors. Known for in-depth fundamental analysis and accurate forecasting, he has provided research coverage on notable public companies, delivering actionable investment insights and strong risk-adjusted return track records. His professional experience includes progressive roles at UBS and prior financial institutions, contributing substantial expertise since entering the industry. Tejas Vyas holds appropriate professional credentials and securities licenses, supporting his credibility and recognition as an effective sell-side analyst.

    Tejas Vyas's questions to REGENXBIO (RGNX) leadership

    Tejas Vyas's questions to REGENXBIO (RGNX) leadership • Q1 2025

    Question

    Speaking for Ellie Merle, Tejas Vyas from UBS asked for clarification on the upcoming RGX-202 functional data release, details on the commercial manufacturing process, and whether Phase I/II patients would be included in the pivotal dataset.

    Answer

    President and CEO Curran Simpson clarified the RGX-202 data update will be a press release in 1H 2025, not at ASGCT, focusing on dose level 2 patients. He confirmed commercial manufacturing will use the same validated process as the pivotal trial and that qualifying Phase I/II patients will be included in the BLA filing dataset.

    Ask Fintool Equity Research AI